Biomarkers In Brain-derived Exosomes Assist The Diagnosis Of Neurodegenerative Diseases | 107915
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Biomarkers in brain-derived exosomes assist the diagnosis of neurodegenerative diseases

Joint Event on 24th World Congress on Pharmacology & 7th World Heart Congress

Gal Bitan, Suman Dutta, Irish del Rosario, Kimberly Paul, Jose-Alberto Palma, Susan L. Perlman, Wayne W. Poon, Horacio Kaufmann, Brent L.Fogel , Jeff M. Bronstein and Beate Ritz

University of California, USANew York University School of Medicine, USA

ScientificTracks Abstracts: Clin Pharmacol Biopharm

Statement of the Problem: Biomarkers for neurodegenerative diseases are urgently needed. Definite diagnosis for most diseases is possible only postmortem and the rates of misdiagnosis are high. Monitoring progression and treatment effects using clinical criteria is inefficient due to high variability. Current biomarker strategies, such as brain imaging and cerebrospinal fluid analysis have major drawbacks. An attractive alternative is analysis of biomarkers in brain-derived exosomes isolated from the blood.

Methodology & Theoretical Orientation: We examined ?-synuclein in neuronal and oligodendroglial exosomes as a diagnostic biomarker for distinguishing between Parkinson???s disease (PD) and multiple system atrophy (MSA). ?-Synuclein deposition is found as Lewy bodies in PD and glial cytoplasmic inclusions, primarily in oligodendrocytes, in MSA. We compared cohorts of healthy control individuals, patients with PD, and patients with MSA.

Findings: ?- Synuclein concentration in both exosome populations were significantly higher in the two diseases than in the controls and in MSA relative to PD. The total ?-synuclein levels separated MSA from control with high sensitivity and specificity, whereas the PD group separated only moderately from the other groups. However, the ratio between the ?- synuclein levels in the oligodendroglial relative to the neuronal exosomes separated the two disease groups with high sensitivity and specificity. The ratio also correlated significantly with progression of motor symptoms in the PD group.

Conclusion & Significance: Measurement of ?-synuclein in brain-derived exosomes offers a minimally invasive means for analyzing biomarkers for PD and MSA, suggesting that in the relatively near future these two diseases could for the first time be diagnosed with high sensitivity and specificity, and their progression could be monitored, using a simple blood test.

Gal Bitan, PhD, received his PhD in organic chemistry from the Hebrew University of Jerusalem, Israel. Following postdoctoral training at Harvard Medical School and affiliated hospitals, he joined the faculty at UCLA where he is currently a Professor of Neurology. Dr. Bitan’s research program focuses on neurodegenerative diseases caused by abnormal protein self-assembly, such as Alzheimer’s and Parkinson’s diseases. He has made seminal contributions to the study of amyloidprotein oligomers and has been developing novel drug candidates and biomarker measurements for these diseases.